Skip to main content

Table 2 Patient characteristics by breast cancer subtype (Number = 819).

From: Implications of constructed biologic subtype and its relationship to locoregional recurrence following mastectomy

Variable All patients (Number = 819) HR+/HER2-
(Number = 574)(%)
HR+/HER2+
(Number = 57)(%)
HR-/HER2+
(Number = 51)(%)
HR-/HER2-
(Number = 94)(%)
P-value
Median age at diagnosis 55 56 54 49 54 < 0.01
T1 615 439 (76.48) 41 (71.93) 36 (70.59) 60 (63.83) 0.06
Positive lymph nodes 230 164 (28.57) 25 (43.86) 14 (27.45) 19 (20.21) 0.02
≥ 4 positive lymph nodes 10 7 (1.22) 0 0 3 (3.19) 0.25
Lymphovascular invasion 137 89 (15.51) 16 (28.07) 13 (25.49) 16 (17.02) 0.07
Modified Black's nuclear grade 3 301 132 (23.00) 36 (63.16) 48 (94.12) 75 (79.79) < 0.01
Close or positive margins 27 17 (2.96) 0 3 (5.88%) 5 (5.32) 0.21
Hormonal therapy 556 473 (82.40) 50 (87.72) 5 (9.80) 6 (6.38) < 0.01
Chemotherapy 390 235 (40.94) 42 (73.68) 38 (74.51) 64 (68.09) < 0.01
Median follow-up (months) 58 58 55 62 53 0.11
Locoregional recurrence incidence rate at 60 months (95%CI) 2.5%
(1.6% to 4.0%)
1%
(0.1% to 1.9%)
6.5%
(0 to 13.5%)
2%
(0 to 5.8%)
10.9%
(3.8% to 17.5%)
< 0.01
Local recurrence incidence rate at 60 months (95% CI) 0.9% (0.5% to 2.1%) 0.5% (0.2% to 1.7%) 4.7% (2.3% to 17.7%) 0% 2.6% (0.7% to 10.5%) 0.06
Regional recurrence incidence rate at 60 months (95% CI) 1.5% (0.9% to 2.8%) 0.5% (0.2% to 2.0%) 1.8% (0.3% to 12.1%) 2.0% (0.3% to13.4%) 8.3% (4.2% to 16.1%) < 0.01
  1. CI, confidence interval; HER2, human epidermal growth receptor 2; HR, hormone receptor.